During the first week of July, an action alert was sent out by the National Legislative Association on Prescription Drug Prices (NLARx) about the need for states to take immediate action on this. The full memo can be read via the link on the Pharmaceuticals and Healthcare Reform page of the NLARx website . Among [...]
Archive for the ‘Health Care Reform’ Category
NLARx Alert:Immediate Action Needed to Preserve State Medicaid Prescription Drug Rebates
Posted in Access to Medicines, Economics of Health Care, Health Care Reform, Health Insurance on 27 July 2010 | Leave a Comment »
In the News
Posted in Access to Medicines, Discrimination, Economics of Health Care, Ethics, Health Care Marketing, Health Care Reform, Health Insurance on 25 April 2010 | Leave a Comment »
Drug Prices Rose 9.1% Last Year, Ahead of Federal Health Overhaul Drug companies sharply raised prices last year, ahead of increased rebates they must pay to Medicaid and other expenses tied to the federal health overhaul passed last month. WellPoint routinely targets breast cancer patients Shortly after they were diagnosed with breast cancer, each of [...]
Update on Biologics Pathway in Health Care Reform
Posted in Access to Medicines, Economics of Health Care, Health Care Reform on 27 March 2010 | Leave a Comment »
As we celebrate the passage of the health care reform legislation, we can’t rest yet. Vigilance is needed to ensure the best provisions are fully implemented, and to continue to work for the full public option and rational use of resources. Alas, a biologics pathway was created in the package, but it is the industry-backed [...]
